Every year, more than 100 million people worldwide are affected by some degree of a  musculoskeletal injury. Also, more than 1 million new prostate cancer and 132.000 skin melanomas are diagnosed annually. Global Cell therapy market is steadily growing at an annual rate of 23%, and is expected to reach U$D 123,7B by 2020, with  musculoskeletal disorders and cancer accounting for the largest growth among all clinical indications.

Figure 1. Cell therapy market size, growth and global opportunity ($Millions). Cancer, Orthopedics, Musculoskeletal, Spine have the biggest growth projected during 2009-2018. Source: MedMarket Diligence, LLC Report #S520, “Tissue Engineering; Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018”

Regenerative Rehabilitation: Musculoskeletal Injuries

The market for musculoskeletal injuries is steadily growing and has become virtually infinite, as offer is really far from covering demand. Osteoarthritis (OA) is a leading cause of disability, 85% of elders over 65 years suffer from knee OA and 80% suffer from spine facet OA. Among professional football players, 60% of them will get seriously injured at least once during their career and 90% of these injuries will be soft tissues, such as muscles, tendons and ligaments. Just in Latam, the global prevalence of musculoskeletal injuries is 30%, almost 190 million people. All the later factors make for a global market value of USD $67,5 Billions with a CAGR of 23%.

Oncology: Skin Melanoma and Prostate Adenocarcinoma

Cancer is the second leading cause of death globally. One in every three cancers diagnosed is a skin cancer and one in every five Americans will develop some kind of skin cancer in their lifetime. Currently, between 132,000 melanoma skin cancers occur globally each year. Prostate adenocarcinoma is the second most common cancer in men. An estimated 1,3 million men worldwide are diagnosed with prostate cancer each year. With an estimated 307,000 deaths in 2012, prostate cancer is the fifth leading cause of death from cancer in men. The global prostate cancer therapeutics market size was valued at USD 7,9 billion in 2016 and is estimated to grow at 4,8% annually to reach USD 12,0 billion by 2025.